Posted by Joerg Wolf in
German Politics, International Economics on Tuesday, April 3. 2007
Robert I. Rotberg with Harvard's Kennedy School of Government writes in The Boston Globe about "Losing the war in Afghanistan:" THE UNITED States and NATO are about to lose the war in Afghanistan to an insurgent, revived Taliban. Deprived of sufficient firepower and soldiers, Allied forces are failing to hunt down and contain the Taliban, especially in the southern part of the country. Moreover, the crucial battle for Pashtun hearts and minds is also about to be lost. Only the rapid provision of security, roads, electricity, and educational and health services can counter the appeal of the renewed and reinvigorated Taliban. Urgently required are more troops for security and more funds for rebuilding essential services.
The op-ed focuses on the drug problem:
Narco-trafficking is fueling the Taliban, and fat profits from poppies and opium are partially responsible for the militants' resurgence. Indeed, Afghanistan is supplying about 90 percent of the world's opium and nearly all of the heroin that ends up in Europe. A recent study by the UN Office for Drugs and Crime forecasts a record crop of poppies this year, on top of last year's bumper harvest. To undercut the ability of the Taliban to purchase arms, pay soldiers, and buy the support of villagers, the United States and NATO need to break the back of the drug trade in and out of Afghanistan. However, reliance on eradication -- the current weapon of choice -- is foolish and wasteful. Uprooting crops and spraying have both had limited local effect. What is needed is a radically new, incentive-based method to provide better incomes to farmers from substitute crops.
Personal comment: So, basically, Europe is financing the Taliban, if the above mentioned numbers are correct. A few months ago, I read some criticism about these statistics, but I don't think it matters much if 90% or "just" 60% of Afghanistan's opium end up in Europe. It is a disgrace that our drug addicts finance criminals, insurgents, terrorists etc.
The "war on drugs" is not very effective, but is doing a lot of harm. A recent example: "Austrian sniper rifles that were exported to Iran have been discovered in the hands of Iraqi terrorists, The Daily Telegraph has learned. More than 100 of the.50 calibre weapons, capable of penetrating body armour, have been discovered by American troops during raids. The guns were part of a shipment of 800 rifles that the Austrian company, Steyr-Mannlicher, exported legally to Iran last year."
Iran has a big drug problem as well. Iranian drug addicts finance the Taliban and others involved in narco-trafficking as well.
Legalizing drugs in Europe would cut the huge profits the Taliban and other middle men make. Adult drug consumers could take their drugs under supervision in European hospitals, who would buy opium and heroin from some small Afghan coops, i.e. providing an income for them. All the money wasted in the "war on drugs" could be used to tell every European once a week that drugs are bad. If they don't listen, it is their problem. I don't mind if people are stupid and ruin their health by taking drugs; that's freedom of choice. I just don't want Europeans to finance militants in Afghanistan and elsewhere, because that causes international problems and makes Europe less secure.
Alcohol is causing big problems in European societies as well, but it is still legal. A few days ago, a sixteen years old Berliner died after drinking dozens of Tequilas in one of the popular "flatrate" parties.
What do you think? Am I underestimating the risks and overestimating the benefits of the legalization of drugs?
UPDATE: Our reader Axel brought us this interesting story in Spiegel International:
Governments in Berlin, Paris and Rome, along with NATO leadership are discussing a potentially explosive new idea: the legalization of Afghanistan's opium production. The plan envisages farmers being able to sell their poppies to officially licensed buyers for the same price they currently get from the drug barons. The product could then be sold to the pharmaceutical industry for pain medication and other products.
Welcome! You are reading the ATLANTIC REVIEW -- a Press Digest on Transatlantic Relations combined with commentary and analysis by three young professionals from Germany, the Netherlands and the United States. More about us.
The horizontal menu bar at the top helps to navigate this site.
Subscribe to one of our RSS-Feeds or to our newsletter, which is emailed twice per month.
Only registered users may post comments here. Get your own account
here and then
log into this blog. Your browser must support cookies.
The author does not allow comments to this entry